Bai Wen-Jun
Research Institute for Male Health, Peking University People's Hospital, Beijing 100044, China.
Zhonghua Nan Ke Xue. 2009 Jan;15(1):92-5.
As a novel phosphodiesterase type 5 (PDE5) inhibitor, tadalafil is administered orally for the treatment of erectile dysfunction (ED). In addition to its outstanding efficacy that lasts 36 hours, tadalafil shows an excellent safety and tolerance, with only a few transient mild to moderate adverse events. Usually ED patients are concomitantly afflicted with multiple pre-existing medical conditions or receive a range of drugs at the same time. Therefore, it is essential to understand its safety in general population and some special high-risk cohorts.
作为一种新型的5型磷酸二酯酶（PDE5）抑制剂，他达拉非通过口服给药用于治疗勃起功能障碍（ED）。除了具有长达36小时的出色疗效外，他达拉非还表现出极佳的安全性和耐受性，仅有少数短暂的轻度至中度不良事件。通常，ED患者同时患有多种并存的基础疾病或同时服用多种药物。因此，了解其在普通人群和一些特殊高危人群中的安全性至关重要。
